Bellerophon Therapeutics Inc (NASDAQ:BLPH) shares rose 12.5% during trading on Wednesday . The company traded as high as $0.65 and last traded at $0.63. Approximately 511,461 shares were traded during mid-day trading, an increase of 56% from the average daily volume of 328,793 shares. The stock had previously closed at $0.56.

BLPH has been the topic of a number of recent research reports. Zacks Investment Research upgraded Bellerophon Therapeutics from a “hold” rating to a “buy” rating and set a $0.75 price objective on the stock in a research report on Thursday, April 11th. Maxim Group set a $3.00 price objective on Bellerophon Therapeutics and gave the company a “buy” rating in a research report on Monday, April 8th.

The stock has a market cap of $41.35 million, a P/E ratio of -1.85 and a beta of -0.02. The company has a debt-to-equity ratio of 0.18, a current ratio of 2.99 and a quick ratio of 2.99.

Bellerophon Therapeutics (NASDAQ:BLPH) last announced its quarterly earnings data on Thursday, May 9th. The biotechnology company reported $0.01 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.10) by $0.11. As a group, equities analysts expect that Bellerophon Therapeutics Inc will post -0.21 EPS for the current year.

Several large investors have recently bought and sold shares of the company. Sabby Management LLC acquired a new position in Bellerophon Therapeutics during the 1st quarter worth $202,000. Renaissance Technologies LLC boosted its position in Bellerophon Therapeutics by 5.0% during the 1st quarter. Renaissance Technologies LLC now owns 1,317,676 shares of the biotechnology company’s stock worth $860,000 after acquiring an additional 62,200 shares during the period. Arch Venture Corp acquired a new position in Bellerophon Therapeutics during the 1st quarter worth $631,000. Geode Capital Management LLC lifted its holdings in shares of Bellerophon Therapeutics by 13.1% in the fourth quarter. Geode Capital Management LLC now owns 232,890 shares of the biotechnology company’s stock valued at $186,000 after buying an additional 27,027 shares during the period. Finally, Vanguard Group Inc lifted its holdings in shares of Bellerophon Therapeutics by 2.5% in the third quarter. Vanguard Group Inc now owns 1,023,533 shares of the biotechnology company’s stock valued at $1,105,000 after buying an additional 25,300 shares during the period. Institutional investors and hedge funds own 54.68% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Bellerophon Therapeutics (NASDAQ:BLPH) Stock Price Up 12.5%” was originally posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this story on another domain, it was stolen and republished in violation of international copyright and trademark legislation. The legal version of this story can be viewed at https://theolympiareport.com/2019/06/12/bellerophon-therapeutics-nasdaqblph-stock-price-up-12-5.html.

About Bellerophon Therapeutics (NASDAQ:BLPH)

Bellerophon Therapeutics, Inc is a clinical-stage therapeutics company, which focuses on developing innovative products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The company engages in two programs including INOpulse and BCM.

Featured Story: What is a Candlestick Chart?

Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.